Prosensa ($RNA), one of a handful of biotechs racing to develop treatments for Duchenne muscular dystrophy, has secured $7 million from a nonprofit to accelerate its R&D efforts. The money, courtesy of CureDuchenne, will help the company launch two studies on PRO044, an early-stage treatment for the muscle-wasting disease, and support a U.S. regulatory filing for drisapersen, the biotech's lead candidate. Prosensa hopes to submit drisapersen by year's end. More